A new blood test developed by researchers at Oregon Health & Science University (OHSU) shows promise for the early detection of pancreatic cancer, a disease notorious for its high mortality rates due to late diagnosis.

The test, named PAC-MANN, which stands for “protease activity-based assay using a magnetic nanosensor,” could provide a critical tool for doctors.

It can potentially lead to improved survival rates for patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), the most prevalent and aggressive form of pancreatic cancer.